Compare UFCS & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFCS | SDGR |
|---|---|---|
| Founded | 1946 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1995 | 2020 |
| Metric | UFCS | SDGR |
|---|---|---|
| Price | $51.39 | $15.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $40.50 | $21.00 |
| AVG Volume (30 Days) | 139.9K | ★ 866.1K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 87.45 | 45.14 |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,386,412,000.00 | $255,869,000.00 |
| Revenue This Year | $11.80 | $0.76 |
| Revenue Next Year | $8.77 | $4.60 |
| P/E Ratio | $45.34 | ★ N/A |
| Revenue Growth | 10.62 | ★ 23.29 |
| 52 Week Low | $26.11 | $10.95 |
| 52 Week High | $54.42 | $23.02 |
| Indicator | UFCS | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 53.14 | 45.00 |
| Support Level | $48.44 | $14.61 |
| Resistance Level | $54.42 | $16.47 |
| Average True Range (ATR) | 1.56 | 0.59 |
| MACD | -0.08 | -0.11 |
| Stochastic Oscillator | 66.46 | 21.62 |
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.